Cytox

About:

Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease.

Website: http://cytoxgroup.com

Twitter/X: CytoxDx

Top Investors: Future Planet Capital, University of Birmingham, UK Innovation & Science Seed Fund, EASME - EU Executive Agency for SMEs, Seneca Partners

Description:

Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.